[
    {
        "other_ids": [
            {
                "name": "Study Protocol Other Identifier",
                "value": "042011"
            },
            {
                "name": "Study Protocol Other Identifier",
                "value": "2011-001699-20"
            }
        ],
        "amendment_date": null,
        "keywords": [
            "Langerhans cell histiocytosis"
        ],
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "North American Consortium for Histiocytosis",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Stratum I"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Patients must be less than 18 years of age at the time of diagnosis."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Patients must have histological verification of the diagnosis of Langerhans cell histiocytosis according to the criteria described in Section 6.1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Signed informed consent form"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Stratum II"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 5,
                    "description": "Patients of Stratum I who have:"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 6,
                    "description": "Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 7,
                    "description": "AD intermediate or worse in non-risk organs or AD better in risk organs after 12 weeks (Initial Course 2)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 8,
                    "description": "Disease progression (AD worse) in non-risk organs at any time during continuation treatment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 9,
                    "description": "Active disease at the end of Stratum I treatment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 10,
                    "description": "Disease reactivation in non-risk organs at any time after completion of Stratum I treatment"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 11,
                    "description": "Stratum III"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 12,
                    "description": "Patients from Stratum I who fulfill the following criteria:"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 13,
                    "description": "AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2)."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 14,
                    "description": "Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 15,
                    "description": "Hb <70 g/L (<7.0 g/dl) and/or transfusion dependency"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 16,
                    "description": "PLT <20 x109/L (20,000/\u03bcL) and/or transfusion dependency (both criteria have to be fulfilled) AND/OR"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 17,
                    "description": "Liver dysfunction (or digestive involvement with protein loss)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 18,
                    "description": "Total protein <55 g/L or substitution dependency"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 19,
                    "description": "Albumin <25 g/L or substitution dependency (at least one of the two criteria to be fulfilled)"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 20,
                    "description": "Stratum IV"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 21,
                    "description": "Patients from Stratum I or Stratum III who fulfill the following criteria:"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 22,
                    "description": "AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2) of Stratum I OR"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 23,
                    "description": "AD worse after the 2nd and 3rd 2-CdA/Ara-C course, and those AD worse or AD intermediate after the 4th 2-CdA/Ara-C course of Stratum III AND"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 24,
                    "description": "Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as defined in Table XI (see Section 10.3.1)."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 25,
                    "description": "Informed consent: All patients or their legal guardians (if the patient is <18 years of age) must sign an Ethics or institutional Review Board approved consent form indicating their awareness of the investigational nature and the risks of this study. When appropriate, younger patients will be included in all discussions in order to obtain assent."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 26,
                    "description": "Adequate organ function: Patients should have adequate hepatic, renal, cardiac and pulmonary function to undergo reduced intensity HCT based upon local institutional guidelines, or at a minimum meet requirements noted in eligibility checklist Appendix A-VIII_1. However, significant hepatic and pulmonary dysfunction, if secondary to underlying LCH disease activity, will not exclude patients from protocol enrollment and should be discussed with the National PI Coordinator and the Coordinating Principal Investigator."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 27,
                    "description": "Stratum V"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 28,
                    "description": "All patients with verified diagnosis of LCH and MRI findings consistent with ND-CNSLCH irrespective of previous treatments (also those not registered to other Strata ofLCH-IV)."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 29,
                    "description": "Patients with isolated tumorous CNS-LCH (including isolated DI with mass lesion in the hypothalamus-pituitary axis). In patients with already established diagnosis of LCH and radiologic finding of CNS lesions compatible with LCH, a biopsy of the lesion is not obligatory. In all other cases a biopsy of the lesion is needed for inclusion into the study"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 30,
                    "description": "Stratum VI -- Patients with newly diagnosed SS-LCH and localization other than \"multifocal bone\",isolated tumorous CNS lesion, or isolated \"CNS-risk\" lesion."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 31,
                    "description": "Stratum VII -- All patients registered in LCH IV (regardless of treatment) as long as consent for longterm follow-up has not been withheld."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 32,
                    "description": "Stratum I"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 33,
                    "description": "Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 34,
                    "description": "LCH-related permanent consequences (e.g. vertebra plana, sclerosing cholangitis, lung fibrosis, etc.) in the absence of active disease"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 35,
                    "description": "Prior systemic therapy"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 36,
                    "description": "Stratum II"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 37,
                    "description": "Patients with progressive disease in risk organs"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 38,
                    "description": "Permanent consequences (e.g. sclerosing cholangitis, lung fibrosis, etc.) without evidence of active LCH in the same organ or in any other locations"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 39,
                    "description": "No written consent of the patient or his/her parents or legal guardian"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 40,
                    "description": "Stratum III"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 41,
                    "description": "The presence of any of the following criteria will exclude the patient from the study:"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 42,
                    "description": "Isolated sclerosing cholangitis without evidence of active hepatic LCH as the only evidence of risk organ involvement."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 43,
                    "description": "Inadequate renal function as defined by serum creatinine > 3x normal for age"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 44,
                    "description": "Stratum IV"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 45,
                    "description": "Pulmonary failure (requiring mechanical ventilation) not due to active LCH."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 46,
                    "description": "Isolated liver sclerosis or pulmonary fibrosis, without active LCH."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 47,
                    "description": "Uncontrolled active life-threatening infection."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 48,
                    "description": "Decreased renal function with a GFR of less than 50ml/1.73m2/min."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 49,
                    "description": "Pregnancy or active breast feeding"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 50,
                    "description": "Failure to provide signed informed consent"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 51,
                    "description": "Stratum VI"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 52,
                    "description": "Patients with SS-LCH who have an isolated tumorous CNS lesion (they are eligible for Stratum V),"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 53,
                    "description": "Patients with isolated \"CNS-risk\" or multifocal bone lesions (they are eligible for Stratum I, Group 2)"
                }
            ],
            "structured": {
                "max_age": "18 Years",
                "max_age_number": 18.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 18.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "0 Years",
                "min_age_number": 0.0,
                "min_age_in_years": 0.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": "The international efforts of the past 20 years have shown that combination therapy with\r\n      vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous\r\n      prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients\r\n      with and without risk organ involvement. It also showed that prolonged treatment in the\r\n      latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease\r\n      reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV\r\n      study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV\r\n      study seeks to tailor treatment based on features at presentation and on response to\r\n      treatment, leading to seven strata:\r\n\r\n        -  Stratum I: First-line treatment for MS-LCH patients (Group 1) and patients with Single\r\n           system (SS)-LCH with multifocal bone or \"Central Nervous System (CNS)-risk\" lesions\r\n           (Group 2)\r\n\r\n        -  Stratum II: Second-line treatment for non-risk patients (patients without risk organ\r\n           involvement who fail first-line therapy or have a reactivation after completion of\r\n           first-line therapy)\r\n\r\n        -  Stratum III: Salvage treatment for risk LCH (patients with dysfunction of risk organs\r\n           who fail first-line therapy)\r\n\r\n        -  Stratum IV: Stem cell transplantation for risk LCH (patients with dysfunction of risk\r\n           organs who fail first-line therapy)\r\n\r\n        -  Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS-LCH\r\n\r\n        -  Stratum VI: Natural history and management of \"other\" SS-LCH (patients who do not need\r\n           systemic therapy at the time of diagnosis)\r\n\r\n        -  Stratum VII: Long-term Follow up (all patients irrespective of previous therapy will be\r\n           followed for reactivation or permanent consequences once complete disease resolution has\r\n           been achieved and the respective protocol treatment completed)",
        "official_title": "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis",
        "_phase_sort_order": 1,
        "collaborators": [
            {
                "name": "Histiocyte Society",
                "functional_role": "LABORATORY"
            }
        ],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "2 Years",
                "name": "Cumulative incidence of reactivations in risk organs",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.",
                "description": "From all treatment stratum via long-term follow up in Stratum VII",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "2 Years",
                "name": "d+100 transplant related mortality",
                "description": "Stratum IV",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Early and late mortality",
                "description": "Stratum II",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Early and late toxicity",
                "description": "Stratum III",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Frequency of ND-CNS-LCH in patients with isolated tumorous CNS-LCH",
                "description": "Stratum V",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Identify possible risk factors for permanent consequences (PC)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Incidence of hematopoietic recovery, and donor chimerism at d+100 and 1 year post RIC-HSCT",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Incidence of Permanent Consequences",
                "description": "All Stratum",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Methods of early identification of ND-CNS-LCH",
                "description": "Stratum V - Exploration of the value of neurochemistry, neurophysiology, and neuropsychology methods in early identification of ND-CNS-LCH and in assessing its severity, and comparison to MRI findings.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Need for systemic therapy later during disease course",
                "description": "Stratum VI",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Number of Participants with Serious and Non-Serious Adverse Events",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "3 Years",
                "name": "Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)",
                "description": "Stratum IV",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Overall Survival",
                "description": "Stratum I",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Percentage of Participants with incidence of chronic GVHD",
                "description": "Stratum IV",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "12 Months",
                "name": "Percentage of Patients with Reactivation Free Survival",
                "description": "Stratum I, II, VI",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Percentage of treatment-related toxicities",
                "description": "Stratum II",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 years",
                "name": "Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.",
                "description": "Stratum II",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Record all occurrence of skin, GI or liver abnormalities fulfilling criteria of Grades II-IV acute GVHD",
                "description": "Stratum IV: Hematopoetic Stem Cell Transplantation for Risk LCH",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Response of isolated tumorous CNS-LCH to 2-CDA",
                "description": "Stratum V",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "9 weeks",
                "name": "Response Rate of Second Cycle",
                "description": "Stratum III",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "2 years",
                "name": "Response Rate to ND-CNS-targeted therapy at 12 and 24 months after start of therapy",
                "description": "Stratum V",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 years",
                "name": "Response rate to the combination of prednisone, vincristine and cytarabine",
                "description": "Stratum II",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions",
                "description": "Stratum V",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "2 Years",
                "name": "The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)",
                "description": "Stratum II",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH",
                "description": "Stratum V",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "2 Years",
                "name": "The type of subsequent intensive and/or maintenance therapy utilized",
                "description": "Stratum III",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "2 Years",
                "name": "Time to complete disease resolution",
                "description": "Stratum III",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "II_III",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 6,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT02205762",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2014-07-01",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "High Risk Childhood Langerhans Cell Histiocytosis",
                    "High-Risk Childhood Langerhans Cell Histiocytosis"
                ],
                "nci_thesaurus_concept_id": "C123395",
                "name": "Childhood Langerhans Cell Histiocytosis with Risk Organ Involvement",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C114483"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C123396",
                "name": "Childhood Langerhans Cell Histiocytosis without Risk Organ Involvement",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C114483"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C129806",
                "name": "Central Nervous System Langerhans Cell Histiocytosis",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3107",
                    "C92944"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C3263",
                "name": "Neoplasm by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Blood Disorder",
                    "Hematologic Disorder",
                    "Hematological Disorder",
                    "Blood Disease"
                ],
                "nci_thesaurus_concept_id": "C26323",
                "name": "Hematologic and Lymphocytic Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C35814"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Hematopoietic and Lymphoid System Tumor"
                ],
                "nci_thesaurus_concept_id": "C35813",
                "name": "Hematopoietic and Lymphoid System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C35814",
                    "C3263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Childhood Tumor",
                    "Childhood Neoplasm",
                    "Pediatric Tumor",
                    "Pediatric Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C6283",
                "name": "Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C89328",
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Childhood Hematopoietic Neoplasm",
                    "Childhood Hematopoietic and Lymphoid Cell Neoplasm",
                    "Pediatric Hematopoietic and Lymphoid Cell Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C9431",
                "name": "Hematopoietic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C6283",
                    "C27134"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Childhood Langerhans Cell Histiocytosis"
                ],
                "nci_thesaurus_concept_id": "C114483",
                "name": "Langerhans Cell Histiocytosis",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9431",
                    "C3107"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Infrequent Tumor"
                ],
                "nci_thesaurus_concept_id": "C7201",
                "name": "Infrequent Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C150692",
                "name": "Tumors Derived from Langerhans Cells",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9294"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Histiocytic and Dendritic Cell Neoplasms",
                    "Histiocytic and Dendritic Cell Tumors"
                ],
                "nci_thesaurus_concept_id": "C9294",
                "name": "Histiocytic and Dendritic Cell Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7201",
                    "C27134"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Pediatric Disease or Disorder",
                    "Pediatric Disease"
                ],
                "nci_thesaurus_concept_id": "C89328",
                "name": "Pediatric Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Langerhans Cell Granulomatosis",
                    "Langerhans Cell Histiocytosis, Not Otherwise Specified",
                    "Langerhans Cell Histiocytosis, NOS",
                    "LCH",
                    "Histiocytosis X"
                ],
                "nci_thesaurus_concept_id": "C3107",
                "name": "Langerhans Cell Histiocytosis",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C150692"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Hematopoietic and Lymphoid System Disease"
                ],
                "nci_thesaurus_concept_id": "C35814",
                "name": "Hematopoietic and Lymphoid System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Disease by Site"
                ],
                "nci_thesaurus_concept_id": "C27551",
                "name": "Disorder by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor_Morphology",
                    "Tumor Morphology"
                ],
                "nci_thesaurus_concept_id": "C4741",
                "name": "Neoplasm by Morphology",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Hematologic Cancer",
                    "Hematopoietic Cancer",
                    "Hematological Neoplasm",
                    "Hematopoietic Neoplasm",
                    "Malignant Hematologic Neoplasm",
                    "Hematopoietic malignancy, NOS",
                    "HEMOLYMPHORETICULAR TUMOR, MALIGNANT",
                    "Hematopoietic and Lymphoid Neoplasm",
                    "Hematopoietic Neoplasms Including Lymphomas",
                    "Hematologic Malignancy",
                    "Malignant Hematopoietic Neoplasm",
                    "Hematologic Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C27134",
                "name": "Hematopoietic and Lymphoid Cell Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C35813",
                    "C26323",
                    "C4741"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Disorder of Central Nervous System",
                    "Central Nervous System Disease"
                ],
                "nci_thesaurus_concept_id": "C2934",
                "name": "Central Nervous System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C26835"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "CNS Tumor",
                    "Tumor of the CNS",
                    "Neoplasm of CNS",
                    "Central Nervous System Tumor",
                    "Neoplasm of Central Nervous System",
                    "Tumor of CNS",
                    "Neoplasm of the Central Nervous System",
                    "Central Nervous System Neoplasm",
                    "CNS Neoplasm",
                    "Tumor of the Central Nervous System",
                    "Tumor of Central Nervous System"
                ],
                "nci_thesaurus_concept_id": "C9293",
                "name": "Brain/Spinal Cord Tumor",
                "type": [
                    "maintype",
                    "subtype"
                ],
                "parents": [
                    "C2934",
                    "C3268"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C92944",
                "name": "Central Nervous System Histiocytic and Dendritic Cell Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9294",
                    "C5503"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Neurological Disorder",
                    "Neurologic Disorder",
                    "Disorder of Nervous System",
                    "Unspecified Nervous System Problem"
                ],
                "nci_thesaurus_concept_id": "C26835",
                "name": "Nervous System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "CNS Hematopoietic Tumor",
                    "Hematopoietic Neoplasm of Central Nervous System",
                    "Hematopoietic Neoplasm of CNS",
                    "Central Nervous System Hematopoietic Neoplasms",
                    "Hematopoietic Tumor of the Central Nervous System",
                    "Lymphomas and Hemopoietic Neoplasms of CNS",
                    "Hematopoietic Tumor of Central Nervous System",
                    "Hematopoietic Neoplasm of the CNS",
                    "Hematopoietic Neoplasm of the Central Nervous System",
                    "Lymphomas and Hemopoietic Neoplasms of the CNS",
                    "Central Nervous System Hematopoietic Tumor",
                    "CNS Hematopoietic Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C5503",
                "name": "Central Nervous System Hematopoietic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27134",
                    "C9293"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Neoplasm of Nervous System",
                    "Nervous System Neoplasm",
                    "Tumor of Nervous System",
                    "Nervous System Tumour",
                    "Neoplasm of the Nervous System",
                    "Nervous System Neoplasms",
                    "Tumor of the Nervous System"
                ],
                "nci_thesaurus_concept_id": "C3268",
                "name": "Nervous System Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C26835",
                    "C3263"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "13-428",
        "active_sites_count": 15,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Drug",
                            "Enzyme Antagonist",
                            "Enzyme Inhibitor Agent"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antipyretic and Analgesic"
                        ],
                        "nci_thesaurus_concept_id": "C2356",
                        "name": "Analgesic and Antipyretic",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2198"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Starasid",
                            "Erpalfa",
                            "ARA-cell",
                            "Udicil",
                            "Cytarbel",
                            "Aracytin",
                            "Cytosar",
                            "Alexan",
                            "Arabine",
                            "Aracytine"
                        ],
                        "nci_thesaurus_concept_id": "C408",
                        "name": "Cytarabine",
                        "description": "An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1557"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Mitotic Inhibitor Agents",
                            "Mitosis Inhibitor Drugs",
                            "Mitosis Inhibitors",
                            "Mitotic Inhibitors",
                            "Antimitotic Drugs",
                            "Mitotic Inhibitor Drugs",
                            "Antimitotics",
                            "Microtubular Function Inhibitors",
                            "Mitosis Inhibitor Agents"
                        ],
                        "nci_thesaurus_concept_id": "C273",
                        "name": "Antimitotic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "DHFR Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C2153",
                        "name": "Dihydrofolate Reductase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C16203",
                        "name": "Clinical or Research Activity",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C43431"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Velban",
                            "Velbe",
                            "Exal",
                            "Velsar"
                        ],
                        "nci_thesaurus_concept_id": "C931",
                        "name": "Vinblastine Sulfate",
                        "description": "The sulfate salt of vinblastine, a natural alkaloid isolated from the plant Catharanthus roseus (Madagascar periwinkle) with antineoplastic properties.  Vinblastine disrupts microtubule formation and function during mitosis and interferes with glutamic acid metabolism. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C932",
                            "C67422"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "ADA Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C2157",
                        "name": "Adenosine Deaminase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Therapy",
                            "Pharmacological Treatment",
                            "Treatment With Medication",
                            "Pharmacological Treatments"
                        ],
                        "nci_thesaurus_concept_id": "C15986",
                        "name": "Pharmacotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C49236"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Indoles"
                        ],
                        "nci_thesaurus_concept_id": "C54677",
                        "name": "Indole Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1915"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunosuppressive Agents"
                        ],
                        "nci_thesaurus_concept_id": "C574",
                        "name": "Immunosuppressant",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Cytotoxic Chemotherapy Agent",
                            "Antineoplastic Cytotoxic Agent",
                            "Cytotoxic Antineoplastic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C186664",
                        "name": "Cytotoxic Chemotherapeutic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Grafting Procedure",
                            "Transplant Procedure",
                            "Surgery, Transplantation",
                            "Transplantation Surgery"
                        ],
                        "nci_thesaurus_concept_id": "C15342",
                        "name": "Transplantation",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C49236"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Tubulin Binding Agents"
                        ],
                        "nci_thesaurus_concept_id": "C25974",
                        "name": "Tubulin Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C273"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antimetabolites"
                        ],
                        "nci_thesaurus_concept_id": "C272",
                        "name": "Antimetabolite",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C186664"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastics",
                            "Anti-Cancer Agents",
                            "Antineoplastic Drugs",
                            "Antiproliferative Agents",
                            "Tumor-Specific Treatment Agents",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Tumor Agents",
                            "Antiproliferative Drugs",
                            "Cancer Drug",
                            "Anti-Tumor Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "TX",
                            "Therapeutic Interventions",
                            "Therapeutic Technique",
                            "Therapy",
                            "Therapeutic Method"
                        ],
                        "nci_thesaurus_concept_id": "C49236",
                        "name": "Therapeutic Procedure",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Glucocorticoid"
                        ],
                        "nci_thesaurus_concept_id": "C521",
                        "name": "Therapeutic Glucocorticoid",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C211"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "HSCT",
                            "Hematopoietic Stem Cell Infusion",
                            "HCT",
                            "Hematopoietic Stem Cell Transplantation"
                        ],
                        "nci_thesaurus_concept_id": "C15431",
                        "name": "Hematopoietic Cell Transplantation",
                        "description": "A method of replacing the immature blood-forming cells lost due to high-dose chemotherapy, and possibly radiation therapy, used to destroy leukemia cells.  The stem cells are given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C165194",
                            "C15388",
                            "C15342"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Mercaptopurinum",
                            "Puri-Nethol",
                            "Leukerin",
                            "Purinethiol",
                            "Mercaleukim",
                            "Purinethol",
                            "Flocofil",
                            "Ismipur",
                            "Mercaptina",
                            "Alti-Mercaptopurine"
                        ],
                        "nci_thesaurus_concept_id": "C195",
                        "name": "Mercaptopurine",
                        "description": "A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C574",
                            "C1556"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Folic Acid Analog",
                            "Folic Acid Inhibitors",
                            "Folate Inhibitors",
                            "Folate Analog",
                            "Antifolates",
                            "Folic Acid Antagonist",
                            "Folic Acid Antagonists"
                        ],
                        "nci_thesaurus_concept_id": "C511",
                        "name": "Folate Antagonist",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C272"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Synthetic Hormone"
                        ],
                        "nci_thesaurus_concept_id": "C548",
                        "name": "Therapeutic Hormone",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C147908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1915",
                        "name": "Aromatic Compounds",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1933"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Leustat",
                            "Leustatine",
                            "Leustatin"
                        ],
                        "nci_thesaurus_concept_id": "C1336",
                        "name": "Cladribine",
                        "description": "A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C1556",
                            "C2157",
                            "C798"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Infusion"
                        ],
                        "nci_thesaurus_concept_id": "C15388",
                        "name": "Infusion Procedure",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C49236"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C78272",
                        "name": "Agent Affecting Nervous System",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C16203",
                        "name": "Clinical or Research Activity",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C43431"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Hormonal Therapy Agent",
                            "Hormone Therapy Agent"
                        ],
                        "nci_thesaurus_concept_id": "C147908",
                        "name": "Hormone Therapy",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Intervention Strategies",
                            "Procedure",
                            "Intervention"
                        ],
                        "nci_thesaurus_concept_id": "C25218",
                        "name": "Intervention or Procedure",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C16203"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1557",
                        "name": "Pyrimidine Antagonist",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C272"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C43431",
                        "name": "Activity",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2198",
                        "name": "Nonnarcotic Analgesic",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C241"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Intervention Strategies",
                            "Procedure",
                            "Intervention"
                        ],
                        "nci_thesaurus_concept_id": "C25218",
                        "name": "Intervention or Procedure",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C16203"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C257",
                        "name": "Nonsteroidal Antiinflammatory Drug",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2356"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1913",
                        "name": "Drug or Chemical by Structure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Substance",
                            "Pharmaceutical Agent",
                            "Pharmaceuticals",
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmacological Substance",
                            "Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Adrenal Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C2364",
                        "name": "Adrenal Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1636"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Clyclooxygenases Inhibitor",
                            "Prostaglandin G/H Synthase Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C1323",
                        "name": "Cyclooxygenase Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C257",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Prednitone",
                            "Decorton",
                            "Predicor",
                            "Econosone",
                            "Ofisolona",
                            "Meprosona-F",
                            "DeCortin",
                            "Prednicort",
                            "Deltacortene",
                            "Decortisyl",
                            "Rayos",
                            "Perrigo Prednisone",
                            "Deltison",
                            "Paracort",
                            "Adasone",
                            "Panafcort",
                            "Deltra",
                            "Predniment",
                            "Cortancyl",
                            "Prednilonga",
                            "Prednidib",
                            "Panasol-S",
                            "Prednisone Intensol",
                            "Dacortin",
                            "Promifen",
                            "Predicorten",
                            "Servisone"
                        ],
                        "nci_thesaurus_concept_id": "C770",
                        "name": "Prednisone",
                        "description": "A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C521"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Radiation-Sensitizing Agents",
                            "Radiosensitizing Drugs",
                            "Radiation Sensitizers",
                            "Radiosensitizers",
                            "Radiation-Sensitizing Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C798",
                        "name": "Radiosensitizing Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Vinca-Site Binding Agents",
                            "Vinca-Domain Binding Agents",
                            "Vinca-Site Binding Agent"
                        ],
                        "nci_thesaurus_concept_id": "C67422",
                        "name": "Vinca-Domain Binding Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25974"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C43431",
                        "name": "Activity",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Therapeutic Interventions",
                            "Therapy",
                            "Therapeutic Technique",
                            "Therapeutic Method"
                        ],
                        "nci_thesaurus_concept_id": "C49236",
                        "name": "Therapeutic Procedure",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Abitrexate",
                            "Emthexat",
                            "Brimexate",
                            "Medsatrexate",
                            "Lumexon",
                            "Texate",
                            "Rheumatrex",
                            "Methotrexate LPF",
                            "Lantarel",
                            "Folex",
                            "Ledertrexate",
                            "Tremetex",
                            "Mexate",
                            "Emtexate",
                            "Farmitrexat",
                            "Trixilem",
                            "Maxtrex",
                            "Fauldexato",
                            "Mexate-AQ",
                            "Amethopterin",
                            "Novatrex",
                            "Metrotex",
                            "Emthexate",
                            "Metex",
                            "Methoblastin",
                            "Folex PFS",
                            "Trexeron"
                        ],
                        "nci_thesaurus_concept_id": "C642",
                        "name": "Methotrexate",
                        "description": "An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities.  Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses.  Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C2153",
                            "C511"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C718",
                        "name": "Organic Chemical",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1913"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Corticosteroids"
                        ],
                        "nci_thesaurus_concept_id": "C211",
                        "name": "Therapeutic Corticosteroid",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2364",
                            "C574"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Indocin"
                        ],
                        "nci_thesaurus_concept_id": "C576",
                        "name": "Indomethacin",
                        "description": "A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C54677",
                            "C1323"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antinociceptive Agents",
                            "Pain-relief Medication",
                            "Analgesics",
                            "Anodynes",
                            "Analgesic Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C241",
                        "name": "Analgesic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C78272"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Alkaloids"
                        ],
                        "nci_thesaurus_concept_id": "C221",
                        "name": "Alkaloid",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1933",
                        "name": "Ring Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C718"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1931",
                        "name": "Antineoplastic Plant Product",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1907",
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Vinca Alkaloids"
                        ],
                        "nci_thesaurus_concept_id": "C932",
                        "name": "Vinca Alkaloid Compound",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C221",
                            "C1931"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immune Mediators",
                            "Immune Modulators",
                            "Immunopotentiators",
                            "Immunomodulatory Agent",
                            "Immunotherapy Agent",
                            "Immunotherapeutic Agent",
                            "Immune Regulators",
                            "BRM",
                            "Biomodulators",
                            "Immunomodulators",
                            "Immunomodulating Agent",
                            "Biological Response Modifier"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug Derived from Natural Products"
                        ],
                        "nci_thesaurus_concept_id": "C1907",
                        "name": "Drug, Natural Product",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Purine Inhibitors"
                        ],
                        "nci_thesaurus_concept_id": "C1556",
                        "name": "Purine Antagonist",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C272"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Stem Cell Treatment"
                        ],
                        "nci_thesaurus_concept_id": "C165194",
                        "name": "Stem Cell Therapy",
                        "description": null,
                        "type": "Procedure/Surgery",
                        "category": "other",
                        "parents": [
                            "C49236"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C121331",
                        "name": "Intravenous Immunoglobulin Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C15986"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Synthetic Steroids",
                            "Steroid Hormone"
                        ],
                        "nci_thesaurus_concept_id": "C1636",
                        "name": "Therapeutic Steroid Hormone",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C548"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Stratum I",
                "description": "Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).\r\nFurther therapy prolongation (12 vs. 24 months) and intensification (\u00b1 mercaptopurine) will further reduce the reactivation rate and the permanent consequences.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Stratum II",
                "description": "A uniform \"intensive\" 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms \"INDOMETHACIN\" and \"6-MP/MTX\" (mercaptopurine and Methotrexate).",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Stratum III",
                "description": "Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.\r\nThe initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Stratum IV",
                "description": "To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Stratum V",
                "description": "Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH\r\n- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice.",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Stratum VI",
                "description": "Natural history and management of \"other\" SS-LCH not eligible for stratum I group 2.\r\nTreatment Options- Management (mostly \"wait & see\" and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.\r\nPatients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.\r\nPatients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2017-02312",
        "why_study_stopped": null,
        "brief_summary": "The LCH-IV is an international, multicenter, prospective clinical study for pediatric\r\n      Langerhans Cell Histiocytosis LCH (age < 18 years).",
        "brief_title": "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis",
        "status_history": [
            {
                "status_date": "2014-07-01T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 1400,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2014-07-01",
        "record_verification_date": "2022-02-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Randomized Controlled Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Other Hematopoietic"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Institutional",
        "completion_date": "2023-07-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]